Kaiser Permanente Washington Health Research Institute will help comprise a recently-announced Infectious Diseases Clinical Research Consortium. The research institute is one of 9 Vaccine Treatment and Evaluation Units (VTEUs) within the new consortium that design and conduct clinical trials to evaluate promising vaccines, treatments, and devices for infectious disease.
The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health (NIH), intends to provide about $29 million per year over the course of 7 years for the VTEU program and the consortium’s leadership group. VTEU investigators will work with scientific experts in infectious diseases to prioritize candidate vaccines, diagnostics, therapeutics, and other interventions to test in clinical trials in the new consortium, according to NIH.
“This flagship program aligns with NIAID’s dual mission of conducting robust, wide-ranging biomedical research on existing infectious diseases while maintaining readiness to respond to emergent disease threats with the quick design and launch of clinical trials,” says NIAID Director Anthony S. Fauci, MD.
Lisa Jackson, MD, senior investigator for Kaiser Permanente Washington Health Research Institute and an internal medicine physician for Washington Permanente Medical Group, will be principal investigator for the Kaiser Permanente VTEU. The research institute is the non-proprietary, public-interest research center within Kaiser Permanente Washington working to produce timely, relevant findings that help people stay healthy and get the care they need.
For the full story, visit the NIH website.